BioWorld MedTech

June 28, 2016

MDT buying distressed Heartware, seeks to rescue heart-pump maker in $1.1B deal

Medtronic plc may be the knight in shining armor that Heartware International Inc. has been looking for – a knight that has swept in to rescue the distressed heart-pump maker in a deal valued at roughly $1.1 billion cash. Read More

TAVR patients with low AS have heightened risk of mortality

Anti-infectives, innovation for antimicrobial resistance

Supreme Court passes on Sequenom despite dozens of amicus briefs

Melinta's bid, adding 'multiple plays' by others, could bring about relief

Financings

Daily M&A

Searching for Superbug's Kryptonite

Product briefs

Heartware: A story with twists, turns

Appointments and advancements

Keeping you up to date on recent developments in Cardiology

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...